StemCell Therapy

This report includes the overall and comprehensive study of the Opthalmology Pacs market with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the Opthalmology Pacs industry and provides data for making strategies to increase the market growth and effectiveness. The Global Opthalmology Pacs market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Opthalmology Pacs market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Get sample copy of Opthalmology Pacs Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/608

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. In addition to this, regional analysis is conducted to identify the leading region and calculate its share in the global Opthalmology Pacs market. Various factors positively impacting the growth of the Opthalmology Pacs market in the leading region are also discussed in the report. The global Opthalmology Pacs market is also segmented on the basis of types, end users, geography and other segments.

Top Leading Key Players are:

Topcon Corporation, IBM corporation, Carl Zeiss Meditec AG, EyePACS, Heidelberg Engineering and more.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/opthalmology-pacs-market

The research report encourages the readers to comprehend the importance of quality, shortcomings if any and deep investigation for every member independently by giving the global data of great importance about the market. Consequently, the research report presents the organization profiles and deals investigation of the considerable number of vendors which can assist the customers with taking better choice of the products and services. The end clients of the global Opthalmology Pacs market can be sorted based on size of the endeavour. The Research report presents the open doors for the players of the global market. It additionally offers plans of action which can be taken and market conjectures that would be required.

Global Opthalmology Pacs market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

By End-Use, market is segmented into:

HospitalsAmbulatory Surgical Center (ASCS) & Specialty ClinicsOthersBy Type, market is segmented into:

Standalone PACSIntegrated PACSBy Delivery Model, market is segmented into:

Cloud/ web based modelsOn-premise modelsOthers

The research report on global Opthalmology Pacs market ensures users to remain competitive in the market. Also report helps to identify the new innovations and developments by existing key players to increase the growth of the global Opthalmology Pacs market. Study report covers all the geographical regions where competitive landscape exists by the players such as North America, Europe, Latin America, Asia-Pacific and Middle East Africa. Thus report helps to identify the key growth countries and regions.

The study objectives of this report are:To study and analyze the global Opthalmology Pacs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.To understand the structure of Opthalmology Pacs market by identifying its various subsegments.Focuses on the key global Opthalmology Pacs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Opthalmology Pacs with respect to individual growth trends, future prospects, and their contribution to the total market.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).To project the consumption of Opthalmology Pacs submarkets, with respect to key regions (along with their respective key countries).To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.

Key points covered in this report:This report provides pin-point analysis for changing competitive dynamicsIt provides a forward looking perspective on different factors driving or restraining market growthIt provides a six-year forecast assessed on the basis of how the market is predicted to growIt helps in understanding the key product segments and their futureIt provides pin point analysis of changing competition dynamics and keeps you ahead of competitorsIt helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

For Any Query on the Opthalmology Pacs Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/608

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

See more here:
Opthalmology Pacs Market 2020 Global Innovations, Competitive Analysis, New Business Developments and Top Companies Global Forecast to 2026 -...

A new research study from Data Bridge Market Research with title Microbiome Sequencing Insights 2019, Global Analysis and Forecast to 2026 provides an in-depth assessment of the Microbiome Sequencing including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. Some of the leading key players profiled in this study:BIOLOG; Cosmosid Inc; Illumina, Inc.; Metabiomics Corp.; Oxford Nanopore Technologies; BaseClear B.V.; BGI; BioMathematica; Charles River; CoreBiome, Inc.; Clinical-Microbiomics A/S; Diversigen; Eurofins Scientific; LABCYTE INC.; Leucine Rich Bio Pvt Ltd.; Microbiome Insights; MICROBIOME THERAPEUTICS, LLC; Thermo Fisher Scientific Inc.; Molzym GmbH & Co. KG; Norgen Biotek Corp.; Phase Genomics Inc.; QIAGEN; Resphera Biosciences, LLC; Shoreline Biome; StarSEQ GmbH; Viome, Inc.; Zymo Research among others.

Ask For Complimentary Sample PDF| Request Athttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-microbiome-sequencing-market

Global microbiome sequencing marketis expected to rise to an estimated value of USD 3455.33 million by 2026, registering a healthy CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the focus of various researchers on utilization of this technology in the development of personalized medicine and dietary applications.

Key Developments in the Market:

Market Drivers

Market Restraints

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-microbiome-sequencing-market

Segmentation: Global Microbiome Sequencing Market

By Sequencing Technology

By Component

By Targeted Disease

By Application

By Research Type

By End-User

By Laboratory Type

ByGeography

Get Full Table Of content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-microbiome-sequencing-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, and Europe.

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:[emailprotected]

See the original post:
Global Microbiome Sequencing Market Growth Drivers, Demands, Business Opportunities and Demand Forecast to 2026|Clinical-Microbiomics A/S; Diversigen;...

Adenovirus vectors have become a popular delivery platform for gene therapy and vaccines. However, many people have preexisting immunity against adeno-associated viruses (AAVs), which could significantly reduce vector uptake and therefore render the therapeutic cargo they carry ineffective. Even in individuals that lack preexisting immunity, the first inoculation of a vector could induce immune responses that can thwart repeat administration.

To overcome that obstacle, scientists at the University of Pittsburgh created a CRISPR-based system that they say could effectively prevent immunity to the viral vector. The CRISPR tool briefly suppressedgenes that are related to anti-adenovirus antibody production and helped achieve better gene therapy uptake in mice. The results werepublished in Nature Cell Biology.

Samira Kiani, the studys co-senior author, has co-founded SafeGen Therapeutics with the goal to bring this platform to the clinic to enable safer gene therapy.

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

Many clinical trials fail because of the immune response against AAV gene therapy, Kiani said in a statement. And then you cant re-administer the shot because people have developed immunity.

One recent case in point is CanSino Biologics adenovirus type 5 (Ad5)-vectored COVID-19 vaccine. In the shots phase 2 trial, about half of the participants had high levels of preexisting Ad5 neutralizing antibody. These individuals were found to produce significantly lower immune responses to the vaccine than did those with low preexisting anti-Ad5 immunity.

Kiani and colleagues set out to modify the gene expression that's associated with an immune response against AAV, but only temporarilyjust long enough for the therapeutic content to do its jobbecause they didnt want to tamper with normal immune functions.

RELATED:Hopkins team invents non-viral system for getting gene therapy into cells

CRISPR, which can edit out a defective gene or add in a functional one, is already being explored as a gene therapy strategy. So the University of Pittsburgh researchers figured they could hit two birds with one stone by utilizing CRISPR to also control the immune response.

They treated mice with the CRISPR-based system and then re-exposed them to AAV, and the animals didnt make more antibodies against the virus. The treated mice were more receptive to subsequent AAV-delivered gene therapy than were the control animals, the team reported.

Gene therapies hold promise as potential cures to many hard-to-treat diseases that would otherwise require chronic treatment. So scientists have been trying to perfect their transport vehicles for better safety and efficacy.

A team led by scientists at the San Raffaele Telethon Institute for Gene Therapy in Italy, for example,attached the CD47 protein to the surface of lentiviral vectors so they could escape detection and destruction by the immune system. And researchersfrom Johns Hopkins University developed a nonviral delivery system that uses a polymer nano-container, whichreleases the therapy once inside the cell.

Now, Kianihopes to validate the CRISPR-based technology at SafeGen. In addition to its potential as a gene therapy delivery platform, the researchers also found that their method can prevent or treat sepsis in mice, suggesting it might also be useful for treating inflammatory conditions.

Read the original here:
Using CRISPR to improve viral vectors for gene therapy - FierceBiotech

Gene therapy generally relies on viruses, such as adeno-associated virus (AAV), to deliver genes into a cell. In case of CRISPR-based gene therapies, molecular scissors can then snip out a defective gene, add in a missing sequence or enact a temporary change in its expression, but the bodys immune response to AAV can thwart the whole endeavor.

To overcome that obstacle, researchers at the University of Pittsburgh created a system that uses CRISPR in a different way. Their system briefly suppresses genes that are related to AAV antibody production so the virus can deliver its cargo unimpeded. These results published today inNature Cell Biology.Many clinical trials fail because of the immune response against AAV gene therapy, said study co-senior author Samira Kiani, associate professor of pathology in Pitt'sSchool of Medicineand member of thePittsburgh Liver Research Center(PLRC) andMcGowan Institute for Regenerative Medicine. And then you cant readminister the shot because people have developed immunity.

So Kiani and her long-time collaborator Mo Ebrahimkhani, associate professor of pathology at Pitt, member of PLRC and the McGowan Institute, set out to modify gene expression related to the bodys immune response to AAV. But this gene is important for normal immune function, so the researchers didnt want to shut it down forever, just tamp it down momentarily.

Since CRISPR is such a convenient system for editing the genome, the pair figured they would put it to use for altering the master switches that orchestrate genes involved in immune response.

Were hitting two birds with one stone, said Ebrahimkhani. You can use CRISPR to do your gene therapy, and you can also use CRISPR to control the immune response.

When the researchers treated mice with their CRISPR-controlled immune suppression system and then exposed them to AAV again, the animals didnt make more antibodies against the virus. These animals were more receptive to subsequent AAV-delivered gene therapy compared to controls.

Beyond gene therapy, the study also shows that CRISPR-based immune suppression can prevent or treat sepsis in mice, highlighting the potential for this tool to be broadly useful for a range of inflammatory conditions, including cytokine storm andacute respiratory distress syndrome, both of which can crop up with COVID-19, though more studies are needed to engineer safety features.

The main goal of this study was to develop CRISPR-based tools for inflammatory conditions, said study lead author Farzaneh Moghadam, a PhDstudent in Kianis lab. But when we looked at bone marrow samples, we saw that the group treated with our tool showed a lower immune response to AAV compared to the control group. That was very interesting, so we started exploring how this tool contributes to antibody formation against AAV and could potentially address safety and efficacy concerns with gene therapy trials.

Kiani co-founded SafeGen Therapeutics with the goal of bringing this technology to the clinic.

This study was supported by National Institute of Biomedical Imaging and Bioengineering, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, and a DARPA Young Faculty Award.

Reference: Moghadam F, LeGraw R, Velazquez JJ, et al. Synthetic immunomodulation with a CRISPR super-repressor in vivo. Nature Cell Biology. 2020;22(9):1143-1154. doi:10.1038/s41556-020-0563-3.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Continued here:
Editing the Immune Response To Aid the Delivery of Gene Therapy Cargo - Technology Networks

TipRanks

As fears of a tech bubble and stretched valuations become the talk of the town, investors are turning to Wall Street titans for guidance, namely Ken Griffin. Founding hedge fund Citadel in 1990, the firm now boasts over $35 billion worth of assets under management.As a 19-year-old sophomore at Harvard University, Griffin began trading from his dorm room with a fax machine, computer and phone. Now, the CEO of Citadel, whose net worth stands at $15.5 billion, is known as one of the Wall Street greats. Looking at the funds performance during the COVID crisis, its even more clear why Griffin has legendary status.Unlike the average hedge fund, which had a negative return of between 3-4% in the first half of 2020, Citadels flagship Wellington fund saw its returns land between 13-14% for the same period.Bearing this in mind, we wanted to take a closer look at three stocks Citadel snapped up recently. Using TipRanks database, we found out that each ticker has earned a Strong Buy consensus rating from the analyst community. Not to mention all three of them boast massive upside potential.AVEO Pharmaceuticals (AVEO)Hoping to provide better outcomes for patients, AVEO Pharmaceuticals advances targeted medicines for oncology and other unmet medical needs. Following an important regulatory milestone, its no wonder all eyes are on this healthcare name.Griffin is among those singing AVEOs praises. Increasing its holding by a whopping 2,357%, Citadel bought up 383,720 shares in Q2. With the total position now landing at 400,003 shares, it is valued at $1,824,013.H.C. Wainwright analyst Swayampakula Ramakanth reminds investors that on June 1, the FDA accepted the NDA for tivozanib, the company's lead candidate, for review, based on the fact that the TIVO-3 study reported positive final overall survival (OS) data. In the study, AVEOs therapy was compared to sorafenib, marketed as Nexavar by Bayer, for the treatment of advanced renal cell carcinoma (RCC) in the third and fourth-line settings.Looking more closely at the data, which was presented at the ASCO 2020 virtual meeting, the final OS analysis resulted in an overall hazard ratio (HR) of 0.97, which favored tivozanib. Ramakanth was encouraged by the OS results as they suggest tivozanib at least has a similar overall relative risk of deaths compared to sorafenib.Considering that TIVO-3 study met both the primary endpoint of progression free survival (PFS) and the secondary endpoint of overall response rate (ORR), with comparable OS to the active comparator, we believe tivozanib would likely get a green light for the U.S. approval, which could be a major catalyst in the next 12 months, Ramakanth opined.Adding to the good news, the dose escalation for the Phase 1b/2 DEDUCTIVE study, evaluating tivozanib in combination with durvalumab, a monoclonal antibody against PD-L1 marketed as Imfinzi by AstraZeneca in hepatocellular carcinoma (HCC), has been wrapped up, with it progressing to Phase 2. As the CDC estimates about 33,000 patients suffer from liver cancer every year in the U.S., Ramakanth sees an additional opportunity.To this end, Ramakanth rates AVEO a Buy rating along with a $12 price target. Should his thesis play out, a potential twelve-month gain of 163% could be in the cards. (To watch Ramakanths track record, click here)Other analysts dont beg to differ. 3 Buy ratings and no Holds or Sells have been assigned in the last three months. So, the word on the Street is that AVEO is a Strong Buy. The $15 average price target is more aggressive than Ramakanths and implies 229% upside potential. (See AVEO stock analysis on TipRanks)IDEAYA Biosciences (IDYA)Next up we have IDEAYA Biosciences, an oncology-focused precision medicine company that develops targeted therapeutics by using molecular diagnostics. Based on the strength of its technology, this name has scored several fans.Reflecting a new position for Griffin's Citadel, the fund pulled the trigger on 248,005 shares in Q2. As for the value of this holding, it comes in at $2,881,818. Writing for Northland Capital, analyst Tim Chiang believes shares are undervalued based on the future potential of its precision medicine oncology pipeline, which targets specific biomarkers. Expounding on this, he stated, IDEAYA is applying its capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality which represents an emerging class of precision medicine targets.Part of what makes IDYA a stand-out, in Chiangs opinion, is the fact that its preclinical programs use its synthetic lethality (SL) platform, which targets tumors with MTAP gene deletion and homologous recombination deficiency (HRD) including BRCA mutations.We believe the longer-term upside potential with IDYA shares is significant given the potential utility of SL. The first clinically validated SL gene pair was PARP-BRCA1/2, and based on the efficacy of PARP inhibitors, the SL approach to treating cancer has achieved substantial commercial validation, the analyst explained.To back this up, Chiang points out that several PARP inhibitors have already been approved for the treatment of tumors with BRCA and other DNA damage repair alterations, including ovarian, breast and pancreatic cancers. These inhibitors include AstraZeneca's olaparib, GlaxoSmithKline's niraparib, Pfizer's talazoparib and Clovis rucaparib. He added, We estimate these four drugs generated over $1.6 billion in worldwide sales in 2019 and are expected to reach over $6 billion in sales by 2024.It should be noted that multiple IND filings are set to come within the next 4-12 months, with IDYAs lead SL candidate, IDE397, which was designed to inhibit MTAP and MAT2A and thus cause the death of cancerous tumor cells, entering the clinic in 2021.It should come as no surprise, then, that Chiang joined the bulls. To start off his IDYA coverage, he puts an Outperform rating and $28 price target on the stock. This target implies a possible twelve-month rise of 141% could be on the horizon. (To watch Chiangs track record, click here)Similarly, the rest of the Street is getting onboard. 5 Buy ratings assigned in the last three months add up to a Strong Buy analyst consensus. In addition, the $25.20 average price target puts the potential twelve-month gain at 116%. (See IDYA stock analysis on TipRanks)Ocular Therapeutix (OCUL)Using its patented bioresorbable hydrogel-based formulation technology, Ocular Therapeutix develops cutting-edge therapies for diseases and conditions of the eye. The progress of its clinical programs has caught Wall Streets attention, with some arguing that now is the time to get in on the action.Griffin and Citadel didnt want to miss out on an opportunity. Snapping up 161,032 shares during Q2, the hedge fund gave the holding a 272% boost. The total position is now comprised of 220,269 shares and is valued at $1,718,098.Representing Raymond James, 5-star analyst Dane Leone cites the potential to address the unmet needs in the dry eye disease indication as a key component of his bullish thesis. The company boasts two assets targeting the condition, OTX-CSI (chronic) and OTX-DED (acute). OTX-CSI incorporates the FDA-approved immunomodulator cyclosporine as the active drug in the intracanalicular insert, which is released for an estimated three months to increase tear production.When it comes to OTX-DED, Leone argues OCUL was clever in pursuing the development of OTX-DED (a low dose form of DEXTENZA, a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus to deliver dexamethasone to the ocular surface for up to 30 days without preservatives) for the treatment of episodic dry eye, as the prior safety data from the DEXTENZA approval enabled management to file a Phase 2-enabling IND by YE20.Speaking to the possible opportunity here, both products could provide revenue generation for physicians in the treatment of dry eyes using procedure CPT code 0356T, which could provide incentive for rapid adoption in the dry eye space that is currently valued at $5.1 billion, in Leones opinion.As for the clinical and regulatory pathway, the Phase 2 trial for OTX-DED is set to kick off in 2H21, slightly after OTX-CSI, which will see a Phase 2 clinical trial evaluating two different formulations initiated by 4Q20. Based on the short treatment duration of OTX-DED, management thinks it will still be brought to market first.To this end, Leone remains optimistic about the companys long-term growth narrative. As a result, he rates OCUL a Strong Buy along with a $15 price target. This figure implies shares could rise 89% in the year ahead. (To watch Leones track record, click here) Turning now to the rest of the Street, other analysts are on the same page. With 100% Street support, or 3 Buy ratings to be exact, the consensus is unanimous: OCUL is a Strong Buy. The $13.50 average price target brings the upside potential to 70%. (See OCUL stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Link:
Global Gene Therapy Market is Forecast to Reach US$ 6.42 billion in 2024, Witnessing Growth at a CAGR of 19.29% Over 2020-2024 - Yahoo Finance

Gyros Protein Technologies AB has announced the introduction of Gyrolab AAVX Titer Kit for adeno-associated virus (AAV) vector titer determination in AAV vector manufacturing. The new Gyrolab AAVX Titer Kit for physical titer determination, one of the critical quality attributes (CQAs) of the FDA process validation guidelines, has a broad applicability across numerous AAV serotypes and adds to the Companys wide range of ready-to-use kits that are already used by scientists and bioengineers in the rapidly growing cell and gene therapy market, where AAV vectors are commonly used.

Gyrolab AAVX Titer Kit supports scientists in the development and production of cell and gene therapies to maximize performance and productivity, and reduces the time needed to produce patient treatments. With compressed development timelines for these therapies, the new kit generates results 4 times faster and requires 10 times less sample compared to traditional ELISA methods, accelerating AAV vector workflows and enabling high quality data to be produced from small sample volumes. Featuring an analytical range of >3 logs, Gyrolab AAVX Titer Kit also minimizes repeat testing compared to ELISA.

Gyrolab AAVX Titer Kit is based on a highly selective AAVX affinity ligand developed with the Thermo Scientific CaptureSelect technology by Thermo Fisher Scientific. These ligands are also the basis of POROS CaptureSelect AAVX Affinity Resin, which is frequently used to purify AAV viral vectors. The AAVX ligand binds with high affinity and selectivity to native and recombinant AAV particles of various serotypes (AAV1 to AAV8, AAVrh10).

Read more:
Gyrolab AAVX Titer Kit Introduced to Support Cell and Gene Therapy Market - Technology Networks

The development prediction report titled Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market 2020 by Company, Regions, Type and Application, Forecast to 2025 focuses on thoughtful insights and facts relating to the market. The report investigates the most recent market patterns such as market development openings, size, share, and drivers. The report throws light on the markets historical data, key vendors, region-wise market, and projections for 2020 to 2025 time-period. Report authors have categorized global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market segments, regions, and product types and distribution channels to provide market analysis and information. All the relevant points of interest market product type, producing price, scope, applications are covered in the report. In the later section, market dynamics are covered including market growth factors, limitations, market opportunities, and challenges are mentioned.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Competitive Rivalry:

The report offers a comprehensive study of prime players operating in this global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market by highlighting their product description, business outline, and business strategy. The report conjointly encompasses the amount of production, future demand, and also the health of the organization. Later, the report highlights all the recent developments, product launches, joint ventures, merges, and accusations by the top players. The leading players are also covered with product description, business outline, and production, company profile, product portfolio, product/service price, capacity, sales, and cost.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/83503

The report analyses every sub-segment regarding the individual growth trends, contribution to the total market, and the upcoming forecasts. For the forecast period, the report offers estimates of global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market value and volume. The report discusses key drivers, market challenges, cost structure, barriers, technology, regions, and applications. It spotlights on effective manufacturing methods, production volume, manufacturing facilities, capacities, pricing analysis, product description.

Top key players involved in the industry are: BioReliance, Richter-Helm, UniQure, Cobra Biologics, MassBiologics, Oxford BioMedica, Lonza, MolMed, FinVector, FUJIFILM Diosynth Biotechnologies, Brammer Bio, bluebird bio, Aldevron, Spark Therapeutics, VGXI, Biovian, Eurogentec, Novasep, PlasmidFactory, Cell and Gene Therapy Catapult, Vigene Biosciences

Segmentation by type and analysis of the market: AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA, Other Vectors

Segmentation by application and analysis of the market: Cancers, Inherited Disorders, Viral Infections, Others

The report offers an exhaustive geographical analysis of the global market, covering important regions such as: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), MENA (Saudi Arabia, UAE, Turkey and South Africa)

Moreover, the report analyzes the worlds main regions contributing to the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market development. These regions are assessed the product price, profit, capacity, production, supply, demand, and market growth rate and forecast, etc. Additionally, manufacturing processes, cost structures, import/export consumption, supply and demand figures, cost, price, revenue, and gross margins are analyzed.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/83503/global-viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-2020-by-company-regions-type-and-application-forecast-to-2025

Key Attributes of Market Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

You May Check Also Other Reports

Global Dehydrated Alfalfa Market Research Report With COVID-19 Update

Global Frozen Meat Processing Equipment Market Research Report With COVID-19 Update

Global External Cardiotocography Market Research Report With COVID-19 Update

Global Glutaric Anhydride Market Research Report With COVID-19 Update

Global Infrared Laser Thermometers Market Research Report With COVID-19 Update

Read more:
Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact...

The success of the approved gene therapies has led to an upward surge in the interest of biopharmaceutical developers in this field, resulting in a significant boost in clinical research initiatives and several high value acquisitions

Roots Analysis has announced the addition of Gene Therapy Market (3rd Edition), 2019-2030 report to its list of offerings.

Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA (AveXis) and ZYNTEGLO (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.

To order this 550+ page report, which features 190+ figures and 355+ tables, please visit this link

Around 470 gene therapies are currently under developmentNearly 45% of pipeline drugs are in the clinical phase, while rest are in the preclinical / discovery stage. Gene augmented therapies presently represent 66% of the total number of such interventions that are in the pipeline. It is worth mentioning that majority of such product candidates are being developed as in vivo gene therapies.

More than 30% of clinical stage pipeline therapies are being designed for treating oncological disordersConsidering the overall pipeline, over 20% of product candidates are being developed to treat various types of cancers, followed by those intended for the treatment of metabolic (15%) and ophthalmic disorders (12%). It is also worth highlighting that adenovirus vectors are presently the preferred vehicles used for the delivery of anticancer gene therapies.

Over 60% of gene therapy developers are based in North AmericaOf the 110 companies developing gene therapies in the abovementioned region, 64 are start-ups, 26 are mid-sized players, while 18 are large and very large companies. Further, within this region, most of the developers are based in the US, which has emerged as a key R&D hub for advanced therapeutic products.

More than 31,000 patents have been filed / published related to gene therapies, since 2016Of these, 17% of patent applications / patents were related to gene editing therapies, while the remaining were associated with gene therapies. Leading assignees, in terms of the size of intellectual property portfolio, include (industry players) Genentech, GSK, Sangamo Therapeutics, Bayer and Novartis, (non-industry players) University of California, Massachusetts Institute of Technology, Harvard College, Stanford University and University of Pennsylvania.

USD 16.5 billion has been invested by both private and public investors, since 2014Around USD 3.3 billion was raised through venture capital financing, representing 20% of the total capital raised by industry players till June 2019. Further, there have been 28 IPOs, accounting for more than USD 2.2 billion in financing of gene therapy related initiatives. These companies have also raised significant capital in secondary offerings.

30+ mergers / acquisitions have been established between 2014 and 2019Examples of high value acquisitions reported in recent past include the acquisition of AveXis by Novartis (2018, USD 8,700 million) and Bioverativ by Sanofi (2018, USD 11,600 million).

North America and Europe are anticipated to capture over 85% of market share by 2030With a promising development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 40% during the next decade. In addition to North America and Europe, the market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

The USD 10 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom gene therapies are likely to be the most promising treatment options for genetic disorders. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles, featuring an overview of the therapy, current development status and clinical results. Each profile includes information on therapeutic indication, targeted gene, route of administration, special designations, mechanism of action, dosage, patent portfolio, technology portfolio, clinical trials and recent developments (if available).

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

or email [emailprotected]

Contact:Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 1091[emailprotected]

Originally posted here:
Gene Therapy Market is projected to be worth USD 10 Billion by 2030, growing at an annualized rate of over 40% - Scientect

LONDON Gyroscope Therapeutics Ltd. is poised to move the field of ocular gene therapy on from the treatment of inherited rare diseases to address more common eye conditions, after receiving FDA 510(k) clearance for its Orbit SDS subretinal delivery device.

Orbit SDS uses a cannula to deliver a therapeutic payload to the subretinal space, which it accesses via a suprachoroidal approach route. A microneedle inside the cannula enables targeted dose delivery.

That eliminates the need for a vitrectomy, and is both faster, easier and safer than the surgical procedure, removing concerns about gene therapy vectors leaking from the subretinal space.

Although vitrectomy has been used to deliver several gene therapies, it is not practical for treating hundreds of thousands of patients with dry age-related macular degeneration (AMD) and other common eye diseases. FDA 510(k) clearance of Orbit SDS now opens the way to scale up administration of ocular gene therapies to much larger indications.

The FDA clearance creates the potential to speed up development and widen patient access. In addition to a replacing a defective gene with a functional one, it will be possible to expand into the routine delivery of therapeutic proteins.

The company says it will use the device in its own clinical trials and make it available to other companies developing cell and gene therapies for eye diseases.

Charlotte Arnold, vie president of corporate affairs at Stevenage, U.K.-based Gyroscope told BioWorld the company now plans to integrate Orbit SDS into its GT005 program in dry AMD. We anticipate starting to generate data delivering GT005 using the Orbit SDS in a planned future cohort in the ongoing phase I/II Focus trial, she said.

Unlike the wet form of AMD that can be treated with anti-VEGF antibodies to prevent neovascularization, there is no therapy approved for dry AMD, which is both a cause of significant visual impairment and a precursor to wet AMD.

GT005 uses an adeno-associated virus to deliver the gene encoding an endogenous anti-inflammatory factor, to restore the balance of a complement system known to be hyperactivated in AMD. The aim is that a one-off treatment will prevent further degeneration.

The FDA nod is an important component of developing gene therapies to help preserve sight, said Khurem Farooq, CEO of Gyroscope. The Orbit [device] is exquisitely designed to target the subretinal space, with the aim of providing precise and consistent dosing, Farooq said.

The clearance for Orbit SDS rests on a phase IIb study of palucorcel (CNTO-2476), in the treatment of geographic atrophy of age-related AMD, an advanced stage of AMD, characterized by progressive loss of retinal pigment epithelium. That leads to loss of photoreceptors, resulting in visual disturbance and difficulty adjusting to low light conditions. Central vision is lost progressively.

The Orbit device was used in the phase I/II trial after initial studies in which palucorel was administered by retinotomy showed there was a risk of retinal detachment. A further study used subretinal delivery, but the technique was judged too technically difficult to take forward.

That led on to the development of Orbit SDS, which was purpose designed for subretinal delivery.

In the 21-patient phase I/II palucorel study the investigators reported that administration to the subretinal site was achieved successfully in most patients and [was] not associated with any moderate or severe, or serious ocular adverse events. The investigators were unable to deliver cells in 3 of 21 participants. Most adverse events were mild and resolved within one month.

Vitrectomy can be associated with an increase in intraocular pressure and accelerated formation of cataracts. No such effects were seen in the Orbit SDS study.

Palucorel is a cell therapy derived from human umbilical tissue that expresses anti-inflammatory factors including interleukin-6, brain-derived growth factor, fibroblast growth factors, and anti-angiogenic thrombospondins. While it showed positive effects in two earlier trials, there were no significant improvements in vision in the Orbit SDS-administered trial.

However, the investigators say, This first in human trial of a suprachoroidal approach for delivery of subretinal liquids was successful from a surgical perspective and clearly demonstrates that subretinal delivery via the suprachoroidal space is feasible.

Gyroscope acquired the Orbit SDA device when it merged with its developer, Orbit Biomedical of Philadelphia in April 2019, to become a fully integrated retinal gene therapy company, with clinical, manufacturing and delivery capabilities.

Orbit Biomedical, now renamed Gyroscope USA Inc., is an ISO 13485 medical device company certified to design, manufacture and distribute ophthalmic surgical instruments.

Following on from the FDA clearance, Arnold said Gyroscope is pursuing a CE mark in Europe for Orbit SDS as well. We also plan to enter into licensing and collaboration arrangements for use of the Orbit SDS by other companies for delivery of gene and cell therapies being developed to treat eye diseases, she said.

Read the original:
Gyroscope Therapeutics FDA clearance puts subretinal delivery device in Orbit - BioWorld Online

Non-Hodgkin lymphoma (NHL) is among the most common cancers in the United States. In 2020, an estimated 77,240 Americans will be diagnosed with the disease and about 20,000 people will die from it.1 Seventy-two percent of patients live for at least 5 years after diagnosis.2 However, the success of treatment varies widely across the many subtypes of NHL. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the most common subtype, have a 5-year survival rate of 63% for all disease stages combined. By contrast, follicular lymphoma (FL) has a 5-year survival rate of 88% for all stages combined. Patients with mantle cell lymphoma, one of the more difficult-to-treat subtypes, have an average survival time of less than 5 years.3

But the treatment landscape is transforming across the entire spectrum of NHL. Novel immunotherapies and small molecule inhibitors are offering both previously treated and untreated patients entirely new options and new combinations. At the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, researchers led by Jeremy Abramson, of Massachusetts General Hospital in Boston, provided a compelling overview of these new and upcoming treatments.4 Their overview, published in the ASCO Educational Book, offered a detailed and vital look at the present and future of NHL treatment.

CAR T-cell immunotherapy has been hailed as a major game-changer for some blood cancers.5 For aggressive B-cell lymphomas, such as DLBCL, anti-CD19 chimeric antigen receptor T cells (CAR-T) are a new option for patients who have relapsed following chemoimmunotherapy or autologous stem cell transplant (ASCT). For this patient group, which has a median overall survival of about 4 months, anti-CD19 CAR-T agents have elicited durable remissions in about 40% of patients.5-7 Clinical trial data has led to the approval of axicabtagene, ciloleucel, and tisagenlecleucel by both the US Food and Drug Administration and the European Medicine Agency. CAR T-cells offer curative intent therapy to patients with relapsed DLBCL who are not eligible for stem cell transplant, Dr Abramson told Cancer Therapy Advisor. Previously these patients only had palliative options available.

Some clinicians envision CAR-T as a potential first-line therapy for patients with DLBCL who relapsed after first-line chemoimmunotherapy. These patients, noted Anton Hagenbeek, MD, PhD, professor of Hematology at Amsterdam University Medical Centers, who was not involved with the review paper, represent one of the highest unmet needs in the treatment of lymphoma to date. And Helen Heslop, MD, who directs the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston, Texas, noted that trials for first-line CAR-T therapy are already underway in acute lymphoblastic leukemia. Not everyone sees this potential. First-line treatment in NHL is generally very effective and much less expensive than CAR T-cells, explained Edward Copelan, MD, who chairs the Department of Hematologic Oncology and Blood Disorders at Carolinas Healthcare System in Charlotte, North Carolina, and who was not an author of the review. Though Dr Copelan emphasized that patients at extremely high risk of relapse following standard immunochemotherapy may respond well to CAR-T therapy.

Dr Abramson and co-authors highlighted a difficult conundrum with regard to DLBCL. Although the addition of rituximab to cyclophosphamide, doxorubicin, hydrochloride, and vincristine sulfate (CHOP) chemotherapy is curative for most patients, the number of patients who may be cured after relapse has declined. Thus improvements in second-line therapy are desperately needed. Several clinical trials are currently evaluating anti CD19 CAR-T for primary refractory or early relapsed aggressive B-cell lymphoma compared with traditional salvage therapy or ASCT. The same approach is being studied for relapsed DLBCL patients who are not transplant candidates.

Whether CAR-T therapy will find a place on the first line of care is another current question. The cost and logistics of CAR-T therapy make it unlikely that this approach will replace R-CHOP as the standard initial treatment, Dr Abramson and colleagues noted. I do not think CAR T-cells will replace frontline chemotherapy, Dr Abramson said. However, the authors note that for patients who do not respond well to initial treatment, such an approach may make sense a possibility that is now being examined in the clinical trial setting. Dr Hagenbeek is more certain about the first-line role for CAR-T therapy, based on the dismal prognosis of DLBCL that is refractory to R-CHOP.

On the subject of CAR-T therapy as first-line therapy, the authors pay special attention to so-called double-hit lymphomas (DHLs), also known as double expressor lymphomas. According to a multicenter study published in 2017, R-CHOP is curative for more patients than conventional wisdom has held.9 Clinical trials are currently investigating the use of anti-CD19 CAR-T early for patients who consistently test positive for disease on PET scans during initial therapy, though Dr Abramson and colleagues call for caution with this approach because the prognostic value of PET/CT scans is controversial. Dr Hagenbeek is optimistic about the potential for CAR-T therapy to improve the prognosis for patients with double- and even triple-hit lymphomas, if applied in the first complete, PET-negative metabolic remission. Because these patients have a relatively small tumor load, this approach could, said Dr. Hagenbeek, completely eradicate minimal residual disease. Its the double-hit patients who Dr Copelan sees as the likeliest candidates for first-line CAR T-cell treatment.

Read more here:
Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans - Cancer Therapy Advisor

Data on all eight patients demonstrate sustained engraftment and supranormal IDUA enzyme expression

Translation of metabolic correction to clinical outcomes in first two patients continues to support potential of hematopoietic stem cell gene therapy in a second neurometabolic disorder

Data support planned initiation of registrational trial in 2021

BOSTON and LONDON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics(Nasdaq: ORTX), a global gene therapy leader, today announced additional interim data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, an investigationalex vivoautologous hematopoietic stem cell (HSC) gene therapy in development for the treatment of mucopolysaccharidosis type I (MPS-I) at theSan Raffaele Telethon Institute for Gene Therapy(SR-Tiget) inMilan, Italy. The readout from the primary endpoint at one year of follow-up is expected in 2021. Today's results are being shared virtually in an invited oral presentation at the 46th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT).

We continue to see encouraging data from the ongoing clinical trial in MPS-I, including promising preliminary clinical effects on motor development, acquisition of cognitive skilIs and growth in the first two patients that were treated now 1.5 and 2 years ago, respectively. Additionally, new preliminary analyses of radiological outcome measures suggest that treatment with OTL-203 leads to stabilization or improvement in disease-related neurological abnormalities, as measured by brain and spine MRI, which we look to confirm with longer follow-up, saidMaria Ester Bernardo, M.D., Ph.D., principal investigator at SR-Tiget. "These data, taken together with those from clinical studies of HSC gene therapy for other metabolic disorders and leukodystrophies, support the potential for this therapeutic approach to correct a wide spectrum of multisystemic manifestations of the disease, bringing clinically meaningful benefits for patients.

Interim Study Results

Eight patients with the severe Hurler subtype of MPS-I had been treated with OTL-203 in the ongoing proof-of-concept study, which completed enrollment in December 2019. As of July 2020, all patients had been followed for a minimum of six months, with the longest follow-up extending out to 24 months. Treatment with OTL-203 was generally well-tolerated with a safety profile consistent with the selected conditioning regimen. Consistent with previous analyses, treatment across all eight patients continued to demonstrate:

We continue to see positive trends in all biomarker and clinical measures as we follow patients in the OTL-203 proof of concept study for longer periods of time, saidBobby Gaspar, M.D., Ph.D., chief executive officer of Orchard. With a growing amount of data to support advancing this program, we have recently convened a panel of disease experts to develop a design for a registrational trial that we intend to take to the regulators in advance of initiating the study in 2021 and ultimately progressing towards commercialization.

About OTL-203 and MPS-I

Mucopolysaccharidosis type I (MPS-I) is a rare, inherited neurometabolic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) lysosomal enzyme, which is required to break down sugar molecules called glycosaminoglycans (also known as GAGs). The accumulation of GAGs across multiple organ systems results in symptoms including neurocognitive impairment, skeletal deformity, loss of vision and hearing, and cardiovascular and pulmonary complications. MPS-I occurs at an overall estimated frequency of one in every 100,000 live births. There are three subtypes of MPS-I; approximately 60 percent of children born with MPS-I have the most severe subtype, called Hurler syndrome, and rarely live past the age of 10 when untreated.

Treatment options for MPS-I include hematopoietic stem cell transplant and chronic enzyme replacement therapy, both of which have significant limitations. Though early intervention with enzyme replacement therapy has been shown to delay or prevent some clinical features of the condition, it has only limited efficacy on neurological symptoms. OTL-203 is an investigationalex vivoautologous hematopoietic stem cell gene therapy being studied for the treatment of MPS-I. Orchard was granted an exclusive worldwide license to intellectual property rights to research, develop, manufacture and commercialize the gene therapy program for the treatment of MPS-I developed by theSan Raffaele Telethon Institute for Gene TherapyinMilan, Italy.

About Orchard

Orchard Therapeuticsis a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Ourex vivoautologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and theSan Raffaele Telethon Institute for Gene Therapy inMilan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters inLondonandU.S.headquarters inBoston. For more information, please visitwww.orchard-tx.com, and follow us onTwitterandLinkedIn.

Availability of Other Information About Orchard

Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (TwitterandLinkedIn), including but not limited to investor presentations and investor fact sheets,U.S. Securities and Exchange Commissionfilings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking Statements

This press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as anticipates, believes, expects, plans, intends, projects, and future or similar expressions that are intended to identify forward-looking statements. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, the therapeutic potential of Orchards product candidates, including the product candidates referred to in this release, Orchards expectations regarding the timing of clinical trials for its product candidates, including the product candidates referred to in this release, the timing of interactions with regulators and regulatory submissions related to ongoing and new clinical trials for its product candidates, the timing of announcement of clinical data for its product candidates, and the likelihood that such data will be positive and support further clinical development and regulatory approval of these product candidates. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development, its supply chain and commercial programs; the risk that Orchard will not realize the anticipated benefits of its new strategic plan or the expected cash savings associated with such plan; the risk that any one or more of Orchards product candidates, including the product candidates referred to in this release, will not be successfully developed, approved or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates or that long-term adverse safety findings may be discovered; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; and the risk of delays in Orchards ability to commercialize its product candidates, if approved. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter endedJune 30, 2020, as filed with theU.S. Securities and Exchange Commission(SEC), as well as subsequent filings and reports filed with theSEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

InvestorsRenee LeckDirector, Investor Relations +1 862-242-0764Renee.Leck@orchard-tx.com

MediaMolly CameronManager, Corporate Communications+1 978-339-3378media@orchard-tx.com

See the rest here:
Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I - GlobeNewswire

The end of the day often comes too fast, and many of us may find ourselves not quite ready to settle down. There may be those last-minute emails to send, dishes to do, others in the household who need your attention, or anxieties about tomorrows to-do list. All of that buzz makes it tough to drift off to sleep.

Thats where before-bed yoga comes in. The gentle physical movement is relaxing itself, and the principles yoga is founded on gratitude, self-compassion, and contentment when practiced before bed can be calming, too, helping to promote sleep, says Carol Krucoff, a yoga instructor certified by the International Association of Yoga Therapists and Yoga Alliance and a yoga therapist at Duke Integrative Medicine in Durham, North Carolina.

RELATED: 9 Ways Practicing Yoga Benefits Your Health and Well-Being

Restorative yoga is becoming more popular, particularly since COVID-19 has people on edge, says Krucoff, who has a gentle yoga class on YouTube. A review and meta-analysis published in May 2020 in the journal BMC Psychiatry looked at 19 studies with nearly 2,000 women with sleep problems and found that, overall, a yoga practice (at any time of the day) improved sleep quality compared with not practicing yoga.

RELATED: The Basics on Hatha, Kundalini, and Other Types of Yoga

Before you try these poses, set the stage for sleep by centering your mind. Krucoff recommends practicing the Three Good Things exercise. The intention is to think about three good things that happened to you that day. It can be as little as having a really great cup of coffee that morning, she says. (For more details, find this how-to from the Greater Good Science Center at the University of California in Berkeley.) It helps alleviate worry and get you into a positive mindset that helps you relax.

Then try these five gentle poses and exercises to get you all set for sleep:

If you can only do one thing to prepare yourself for sleep, take a few minutes to work on your breath, says Krucoff. What shes referring to is the relaxed abdominal breath, also known as the yoga belly breath. During the day, you are likely in the habit of breathing shallowly from your chest, but deeper breaths fill the lungs completely. This triggers a cascade of physiological changes. Your heart rate slows, your blood pressure decreases, and muscle tension eases, she explains.

How to Do It Lying down, put one hand below your belly button. Breathe in through your nose to fill your lungs (your belly should rise). Breathe out through your nose. Repeat for a few minutes.

RELATED: 7 Quick Stretches for Stress Relief You Can Do Right Now

Here, youll take your joints through their full range of motion. This is something thats quieting, releases tension and tightness, and is convenient because it can even be done lying down in bed, says Krucoff. Whats more, it helps bring attention to body sensations, making you consider not just whatever happened with your family or at work, or what was on the news over the course of the day, but also how your body actually feels. Are certain muscles sore? Are certain muscles tired? Many of us spend much of our day in our heads, Krucoff says. This practice guides you back into your body, which is a good way to prep for sleep.

How to Do ItLie down on the floor or in your bed. Circle your ankles. Extend your legs out long then bend your knees. Lift and lower your hips to make circular movements. Bend your elbows, then extend your arms long at your sides. Shrug and circle your shoulders. Repeat as needed and as feels good.

If you have back issues, the knee hug will feel particularly nourishing, Krucoff says. In fact, low back pain is one of the most common reasons for seeing a doctor; it also keeps people out of work, according to the National Institute of Neurological Disorders and Stroke. Working hunched over at a desk all day can cause the ache. This pose will relieve it.

How to Do ItLie down and hug one or both knees into your chest. (Whether or not you do one or both depends on your physical abilities.) If you can hug both knees into your chest at the same time, rock from side to side to massage your spine.

RELATED: The Best Home Remedies for Back Pain

Its common to hold tension in your neck and shoulders, says Krucoff. Its even more common for tightness and pain to creep up here if you spend your day working at computer or staring at your smartphone.

How to Do ItSit on your bed, sitting up straight with good posture. Inhale and bring your shoulders up to your ears and squeeze your arm and shoulder muscles tightly. Exhale and release your shoulders, pulling your shoulder blades downward. Repeat a few times.

If you practice yoga, you know this as Savasana, which is the final pose of class. It looks extremely easy to lie down and do nothing, but its among the hardest poses to master because it requires you to release all physical and emotional tension and let go of mental thought, explains Krucoff. But no need to stress about getting Savasana right: Just lie down, be still, and try to not think about anything in particular and it will help you relax. Krucoff calls it relaxed alertness which might sound contradictory but is really about noticing whatever thoughts and feelings do come up without dwelling on any one particular one.

How to Do ItLie down with your arms at your sides, palms up and relaxed. Close your eyes and focus on the rise and fall of your breath. If you have trouble with intrusive thoughts, acknowledge their presence and picture them floating away.

RELATED: Yoga Poses for Beginners

View original post here:
Yoga Poses and Exercises to Help You Sleep - Everyday Health

This article was originally published here

Eur J Cancer Care (Engl). 2020 Sep 3:e13299. doi: 10.1111/ecc.13299. Online ahead of print.

ABSTRACT

OBJECTIVE: Over recent decades, supportive care and patient quality of life, advocated by dedicated guidelines, have become a core focus of the concept of integrative medicine. The Calista 2 survey was conducted in France between September 2016 and October 2017 among oncologists and their patients being treated for early breast cancer, adjuvant colorectal cancer or advanced lung cancer. The present analysis sought to ascertain, understand and rank the expectations of cancer patients with regard to supportive care.

METHODS: Data were collected from 467 questionnaires from patients recruited by 82 oncologists. Inclusion criteria were patients already on treatment for breast cancer, colorectal cancer or lung cancer. Most supportive care facilities were available at the point of care.

RESULTS: Physicians were mainly seen to offer management of adverse events (81%), and pain (72%), psychological support (56%), and advice on diet/nutrition (49%). Patient uptake of supportive care related essentially to management of adverse events (72%) and pain (61%), diet/nutrition (34%), and self-image improvement techniques (31%). The main unmet needs voiced by patients were information on complementary medicines (28%), management of fatigue (27%), and relaxation techniques (24%).

CONCLUSION: Supportive care was essentially seen to satisfy patient requirements with regard to the management of adverse events and pain. However, patients highlighted the need for a wider access to fatigue management and information on complementary medicine and relaxation techniques.

PMID:32885521 | DOI:10.1111/ecc.13299

Read more here:
Patient perspectives on supportive care in cancer: Results of the Calista 2 study - DocWire News

Taylor Brune @heartsinbloomhealth is many things. To start, perhaps above all else, she is passionate about healthcare. Brune, who recently survived COVID-19, suffers from chronic autoimmune deficiencies, which began from a bite from a tick. As a result, she has had to learn and research much in the medical world so that she is as well equipped as possible to survive her severe afflictions.

On top of all that, Brune is also a Medical Assistant. In this capacity, she works with healthcare providers as a liaison to patients, in administrative capacities and other roles to ensure the facility operates smoothly. Brune, never one to shy away from a challenge, is also a student continuing her education. She is using her experience as a Medical Assistant to help transition to, one day, becoming a doctor. That is her ultimate aim.

We caught up with Brune to ask her about this long professional journey, her fight with COVID-19, her passion for healthcare and much more.

@heartsinbloodhealth

When and why did you decide you wanted to be a Medical Assistant?

The last ten years, I have dealt with my own health issues and my own health journey of developing chronic disease and autoimmune disease after a bite from a tic. So, when I lost my health, I was engulfed in the medical world and I was a patient 24-7 and having to do research for myself and be my own health advocate. In the process of learning how to heal myself, I grew the passion of wanting to help heal others.

While I was going through treatments, I was like, this is my calling. This is where Im supposed to be. This is why Im having my health issues and going through this huge life transition and transformation. When that realization happened, I decided to learn about medicine and how to switch my degree over to pre-med and integrative health.

Going into medical assisting school, was the first step in my path. And Im going to be a doctor one day no matter how long it takes! No matter what challenges I face, I know that everything Im going through in my own health is helping me transform into the best person that I can be so that I can be the best doctor for patients. Since Ive had the perspective of being a patient for so many years, I know exactly what theyre thinking and feeling.

If youre interested in becoming a medical assistant here is an awesome guide to start your research - it answers questions like,

After you read this interview go to the full Medical Assistant Career Guide.

Show Me Medical Assistant Programs

What was the process like for you to become a Medical Assistant?

First, I prayed a lot about it. I knew I wanted to switch my degree to pre-med but, I also wanted to work in the medical field a lot sooner. Becoming a doctor takes years in pre-med and medical school.

So, I figured the first step to completely immerse myself in the medical field as soon as possible was to complete a medical assistant program and to actually start working in the field that I love so much. Once I graduated from my medical assistant and phlebotomy program I immediately started working in the field. The experience Ive gained has just confirmed that this is where Im supposed to be and I love it!

How long did the process take, what type of schooling did you?

For medical assisting in California , I needed to go to a medical assisting school. I went to a trade school and enrolled into a medical assisting program. Medical assisting programs are more about gaining hands-on experience in an actual doctors office. This is how the program was set up,

The program style was really beneficial to help me to get on-the-job training and also land a great position right after graduation,

At the same time, though, Ive been going to Arizona State University Online to finish my Bachelors degree, which Ill be finishing in the fall. This fall, Ill have my Bachelors as well as my medical assisting diploma.

As a medical assistant its important to be certified. I took a national certification exam and every two years, I complete the required credits and retake the test to keep my certification up to date.

@heartsinbloodhealth

How did you land your first job as a Medical Assistant?

It was actually pretty easy for me because I seem to interview really well with medical places. My first job was working at a naturopathic office. Next, I went to primary care and oncology. So, thats where Ive been working the last year. Now, Im at Scripps Health Hospital in dermatology.

Theres a lot to know for the job and you have a lot of responsibilities - from first-aid to computer work to patient liaison. Do you like having all these aspects to your workday?

I love it! I have gained so much experience including,

Drawing blood is my absolute favorite because I really enjoy direct patient care. But, overall working with different modalities, systems and technologies has taught me so much about the medical field. Each private practice is completely different and the providers are unique in that they offer different specialties and treatments. Its been fun learning all these different skills.

@heartsinbloodhealth

Your long-term goal is to be a doctor. How did you choose becoming a medical assistant for that aim and how has it helped?

There are a few reasons why I chose medical assisting as my first step towards my goal of becoming a doctor,

What do you like least about being a Medical Assistant or the healthcare field, in general?

For my own personal experience, I have an immune compromised self. I just dont like that I pick up illnesses so easily. I even picked up COVID. Flu season is also difficult for me. Im thankful for the fact that everyone is now taking more precaution in the medical field. Ive observed that people are more mindful of sanitizing and patients are wearing masks. It gives me hope that at least this year I will have stronger defenses and not catch as many illnesses. But theres many great things about working as a medical assistant, too. Each person has their own experience.

As a chronic illness patient myself, the one negative that I dont like is that I feel some doctors dont have time to really hear their patients. When Im a doctor, that is something that I really want to change. However, Ive been really fortunate to work with providers who are integrative in their mindset and do give their patients time. Even now, working with providers who arent integrative, they still give patients time and hear them. Ive been really fortunate to work with good providers. But, from the perspective of a patient, I had to go through multiple providers to get to good ones - and, I didnt like that.

@heartsinbloodhealth

What advice do you have for other people looking to become a Medical Assistant today - first steps, things to keep in mind?

One of the main things is to really look inside yourself and question yourself. Ask yourself really important questions like,

@heartsinbloodhealth

As you said, you recently recovered from COVID-19. What was that experience like for you personally and professionally?

In the beginning of the year, we actually started seeing patients have lung flues and pneumonias with weird symptoms and they were just really sick in January. I believe that COVID-19 was definitely here in the United States in California in January. But we didnt know what it was yet. But then when they started announcing it in February, we definitely got more traffic in the office and we were taking care of patients - even though it was primary and oncology, a lot of the patients in the beginning stages when they were starting to get sick would come to us. So, we were being exposed to COVID-19 and it spread through the staff.

The COVID-19 symptoms started out mild for me. I just figured it was the stress from working and being the only medical assistant since we were short-staffed during that time. Then once the rest of the clinic tested positive, I was like, Oh, no! I think I may have it!

I got tested. The week after I tested positive the illness became super severe for me. I have asthma and type-one diabetes - it went straight into my lungs. I decided to just face it and not be crippled by fear. I set my mind to believe that I would not die from it. Because Id learned with my chronic illness that you just have to stay positive no matter how grim it looks. And really just focus on what you can do to heal.

During the time when it was really severe, I went to the hospital and towards the end, I was able to go home and recover.

Now, its been three months since I've been cleared. I still have lung damage. My body is still healing. My body is still recovering from it in that aspect. But I was very fortunate because Ive had over ten years of experience being a chronic illness patient and working in the medical field. With that experience in mind, I knew how to take care of my immune system and listen to my body. When I got it, it was the beginning of the pandemic when doctors really didnt know anything about it. They didnt know what to tell me. They didnt know how to help me. So, for a lot of it I was on my own. I had to figure out how to survive COVID-19.

Luckily, my knowledge and prayer and by the grace of God and blessings, I was able to fight it, survive it. I was able to apply my knowledge to quickly do a regimen of trying to boost my immune system fast. I made a point to not stress, not think negatively, not fear, and not feed into any of that. I just tried to stay calm through the whole thing. Eventually, after 70 days, I was cleared.

What was the most difficult symptom of COVID-19 for you?

I think, honestly, the worst part was not being able to breathe. Even now, its still hard to breathe. It felt like I was suffocating 24-7, there was no relief. I was even on a breathing machine, not a ventilator, but a nebulizer breathing machine every four hours and taking medication just to be able to survive. I probably should have gone on a ventilator at that point because my oxygen stats were just in the 80s and so low and I was so sick. But I just didnt want to go on the ventilator. When I went into the hospital, they gave me fluids, took all the tests to make sure there was no other organ damage.

So, it was just kind of traumatic, honestly! But I learned a lot. Im grateful to be alive. Im grateful to be able to help anyone, you know? Or to face it without as much fear, even though it is really scary. To have hope and to try to stay calm.

You seem connected with people, both in-person and digitally. How has this helped, how has Instagram helped spread your story?

Its so amazing because I just started sharing my story of being a chronic illness patient and so many people could relate to that. Then when I started sharing my story and my experiences working in the medical field so many more people would message me and connect with me. Ive met so many amazing people, its amazing whats come out of Instagram. Whats come out of this community is just so many different opportunities and abilities to be able to hear other peoples stories, share my story, be able to learn from others, be able to help others. Its made me a better person and its also helped me be able to have a stronger voice.

When youre about to start your day, what is the final thing that passes through your mind before you open the doors to work?

Every morning, I just say a prayer, walking in, in my mind. And I dont know if this is going to sound corny but because this is my calling, I really, truly want to make the most of my job.

I pray right before I walk in every single morning that God uses me as a light of warm light and love to each person that I come across so that my day is very purposeful and meaningful and that Im able to uplift someone in some way. Or help someone in another way or just comfort a patient in a way that they need. I pray every day that my light shines through to the patients and staff around me.

Still have specific questions about becoming a medical assistant? Read our ultimate guide to becoming a Medical Assistant now.

Show Me Medical Assistant Programs

View post:
This Is Why I'm Working as a Medical Assistant While I Advance My Education - Nurse.org

September is National Self Care Awareness Month, traditionally a time when "back to school"has always meant personal renewal, stretching yourself, and trying new things. Here's how to take care of yourself by eating a whole-food plant-based diet, according to Dr. Sari Eitches, an LA-based integrative internist whopromotes wellness through lifestyle choices and takes a holistic approach to personal health.

In an exclusive interview with The Beet, Dr. Eitches, a long-time vegan, talks about guiding her patients to a plant-based lifestyle, as well as what to look out for when transitioning to a vegan or plant-based approach to eating, and her love ofvegan cuisine from around the world. She leads by example and shows that a plant-based diet can optimize our bodys self-healing properties, by lowering inflammation and adding antioxidants to every meal.Lether advice will inspire you to nourish your body and start adding plants to your meals, and take care of you.

Dr. Eitches: I was just finishing my first year as a medical student and I was the least healthy I'd ever been. I was super addicted to caffeine and getting by with convenience food. One week, I signed up for a yoga retreat to reset and relax. The retreat center had a vegetarian dining hall and my teacher was a long-time raw vegan. I intended to eat a raw diet to cleanse at the week-long retreat, but I felt so incredible that I continued to follow the raw diet for two years and remain vegan 14+ years later.

Dr. Eitches: I was pretty fascinated by the vast data that the majority of chronic conditions that Americans suffer from can be controlled, prevented, or even reversed with lifestyle changes including a plant-based diet. We literally are what we eat. The food choices we make (or are made for us) can either cause inflammation and accelerate chronic disease or, if we choose whole food plant-based diet, for example, our foods can slow, reverse and prevent chronic diseases. I now see it in my office every day.

Dr. Eitches: I think of my role as a holistic approach to primary care. I get to learn about my patient's backgrounds, families, hobbies, and values. I understand their health goals and concerns in this context. I do have conventional training as a board-certified MD and run standard tests and prescribe medications when needed. I also have a board certification in integrative holistic medicine, which I lean into, to recommend supplements and refer to complementary healing modalities. With all of my patients, I always address optimizing nutrition, activity, sleep, and mental wellness.

Dr. Eitches: My nutrition plans are evidence-based and customized for each patient's preferences and underlying conditions. For instance, I recommend a plant-based diet for heart disease, diabetes and cancer, but a gluten-free diet for Hashimoto's, or a dairy-free diet for acne, or a low-FODMAP diet for IBS. In all of these cases, I recommend a three-month trial of the diet to see whether we see a difference in their symptoms or labs. I try to balance these recommendations by focusing on the healthful foods to include rather than on what to avoid. We need to be aware that restrictive diets can be isolating and triggering for some people, so there is no one-size-fits-all.

I do think that everybody should eat more greens and fruits and veggies and that nobody should consume dairy. There is great evidence that a whole-food, plant-based diet decreases cholesterol and blood sugar, decreases cancer risk, decreases inflammation and improves bowel regularity. When a patient is ready to try a plant-based lifestyle I am so excited to guide and encourage them on this journey.

Dr. Eitches: Start with adding plants to every meal. Think about the different types of plant foods: Fruits, veggies, greens, legumes, grains, and nuts, and explore all of them. Get excited about a recipe or a farm-share. Some non-vegan foods are simple to swap out such as dairy for plant-based milk and others can be slowly crowded off of the plate.

Dr. Eitches: I recommend that all vegans have their B12 and homocysteine levels checked yearly. Ideally, our B12 levels should be over 400, and homocysteine should be below 8. We should take a B12 supplement, such as a methylcobalamin lozenge or spray to get to these goals. B12 is hugely important for our energy levels, mood, and neurologic function. I often will check omega 3's, vitamin D and iodineas all of these levels tend to be lower in vegans.

Dr. Eitches: There is some meal planning that has to happen around traveling and events, but it's pretty easy to plan ahead. I do make sure to always have vegan cupcakes on hand, either as a mix or in the freezer, so that my kids never feel left out at a birthday party.

Dr. Eitches: I eat plenty of legumes, especially lentils, black beans and edamame. I sometimes add pea protein to my smoothies. I also love (sprouted, organic, non-GMO) tofu and seitan.

Dr. Eitches: I love food, so I can't pick just one. I do love to make a huge green salad and tofu scramble, which I have a few times a week. I live in LA, where it is easy to order amazing vegan food. Some of my favorites are Thai eggplant with brown rice or papaya salad, Ethiopian platters, Japanese ramen and veggie sushi, Indian bharta or bhindi, and Mexican fajitas or burritos.

Dr. Eiches: I would like my life to be a statement of love and compassion and where it isnt, thats where my work lies. -- Ram Dass

Read more:
September is Self Care Month. Here's how to Eat for Wellness - The Beet

How three equine athletes returned from injury to the show ring

At some point in your horse care journey, youve likely ridden a beautiful round, brought your horse in from turnout, or unloaded him from the trailer and realized something was off. Maybe it was a lame step or the slightest bit of swelling but, either way, it prompted a call to your veterinarian. If you were lucky, the root cause was something minor that would resolve with time off and anti-inflammatories. With the more challenging cases, however, you and your veterinarian might have pursued further diagnostics to determine the cause.

After reaching a diagnosis and settling on a treatment plan, you began the arduous process of healing and rehabilitation. This stage can be trying for even the most patient equestrian. But, with a good equine care team and some time, it can be smooth and fruitful.

To see what effective rehabilitation looks like, we found three real-life examples of equine athletes that made full recoveries from their injuries. Well share each ones diagnostic challenges, rehab modalities, and recovery details.

Chanel, a 10-year-old Quarter Horse mare competing in Western pleasure, had been struggling for years with a nagging intermittent left front lameness. Her owner and veterinarian managed this with routine coffin joint corticosteroid injections for about two years. However, the injections ultimately proved to be ineffective at keeping Chanel completely sound and comfortable, so she was referred to Carrie Schlachter, VMD, Dipl. ACVSMR, who founded and designed Circle Oak Equine Sports Medicines rehabilitation and fitness programs and also founded Animals In Motion, a practice that focuses on integrative sports medicine, rehabilitation, and injury prevention.

The case was pretty routine, says Schlachter. We nerve-blocked (used local anesthesia to numb and pinpoint the painful area) her foot, then we X rayed the area, and the X rays showed some mild abnormality in her coffin bone. We recommended an MRI so we could look at the area more deeply.

The MRI showed that Chanel actually had two injuries to her left front foot. The first was mild coffin bone bruising and remodeling in the area we had been looking at radiographically, Schlachter says. But, on the opposite side of the foot, she also had a collateral ligament injury. Collateral ligaments are located on either side of most joints.

This was the aha! moment, she says: Without the MRI I wouldnt have known about the collateral ligament injury so, because the owners were willing to do the MRI, I was not only able to confirm my diagnosis of the bone bruising and remodeling but I was also able to see the reason for it.

Chanel had likely been compensating for the collateral ligament injury by bearing more weight on one side of her foot, creating the bruising in the coffin bone. The injections helped initially because they suffused the area with steroids, reducing inflammation and allowing her to continue working soundly for a brief period.

With a diagnosis in place, Schlachter recommended putting Chanel in a bar shoe to support and stabilize the collateral ligament and the coffin bone. She and her team also injected the coffin joint and the collateral ligament with autologous protein solution (a biologic therapy that stimulates the bodys production of anti-inflammatory mediators and growth factors) and treated the area with extracorporeal shock wave therapy (believed to improve new blood vessel growth, recruit mesenchymal stem cells, and have pain relieving effects).

Schlachter also recommended for Chanel a controlled exercise program, which she modifies to meet the needs of different injuries and disciplines but typically involves:

Two months post-diagnosis, Schlachter reevaluated Chanel. At that point she was 80-90% better, so we allowed her to be walked under saddle for the next two months, she says. When we looked at her again at the four-month mark, she was 100% sound, so we started her on some trot work.

Once she was sound at the canter, Chanel began working back into training. Eight months post-diagnosis she was still sound and back in the show ring. She is now free of bar shoes, and her only maintenance since recovering has been a round of hock and sacroiliac joint injections to manage normal wear and tear.

Chanel was a wonderful patient, Schlachter says. She is the picture perfect example of what a good diagnosis, good treatment, compliant owners, and a well-behaved horse can do.

Melissa King, DVM, PhD, Dipl. ACVSMR, is an associate professor at the Colorado State University (CSU) Veterinary Teaching Hospital, in Fort Collins, where she specializes in equine sports medicine and rehabilitation. King treated JR, a 16-year-old Thoroughbred who had shown as a four-star eventer. From repetitive use in his job, JR developed an insertional lesion in his deep digital flexor tendon (DDFT, which runs from the knee down the back of the leg and around the navicular bone, attaching to the coffin bone) and a second, discrete tear at the pastern level. This article continues in the August 2020 issue of The Horse: Your Guide to Equine Health Care. Subscribe now and get an immediate download of the issue to continue reading. Current magazine subscribers can access the digital edition here.

See original here:
The Journey Back: Three Horses Go From Rehab to Recovery - TheHorse.com

J.D. Prose|Beaver County Times

U.S. Rep. Conor Lamb has co-introduced a trio of bills with three different Republican colleagues to help veterans gain mental-health services and improve government suicide prevention efforts.

In the past week, Lamb, D-17, Mount Lebanon, has teamed with Pennsylvania Rep. Brian Fitzpatrick, R-Bucks County, on the Testing, Researching and Expanding Alternative Treatments (TREAT) Act; Rep. Mike Bost, R-Ill., on the VA Precision Medicine Act and Rep. Jim Banks, R-Ind., on the VA Data Analytics and Technology Assistance (DATA) Act.

We must do more to combat the veteran suicide crisis, said Lamb, a Marine Corps veteran and vice chairman of the House Committee on Veterans Affairs, in a joint statement. Congress needs to give the (Department of Veterans Affairs) every tool possible to meet the mental health challenges facing our veterans before they get to the point of danger.

Lamb added that the work is critical, and it is bipartisan because we all know that one more veteran lost to suicide is one too many.

Fitzpatrick said that "it is imperative that our nations veterans receive access to the highest quality medical testing and holistic treatment options, including for mental health.

Under the TREAT Act, the Department of Veterans Affairs (VA) would be required to create a two-year program to provide complementary and integrative care services for treating post-traumatic stress disorder, depression and anxiety, as well as to conduct a study on treatments such as yoga, meditation, acupuncture, chiropractic care and others that address mental and physical conditions.

The VA Precision Medicine Act would direct the VA to establish the Precision Medicine Initiative for Veterans that Lambs statement said would identify and validate brain and mental health biomarkers among veterans, with specific consideration for depression, anxiety, PTSD, TBI (traumatic brain injuries), and bipolar disorder.

That bill also would have the VA create a robust data privacy and security measures to ensure veterans personal information is kept secure.

The VAs capacity to contract and work with academic and research groups on analyses and data evaluation would be expanded under the DATA Act.

Read the rest here:
Lamb partners with GOP colleagues on three veteran-focused bills - The Times

CoachCare, a virtual health and remote patient monitoring platform for providers and patients across specialties, today announced survey results for over 1,400 patients currently undergoing virtual visits on the CoachCare platform during COVID-19. According to the survey, the patient response to virtual visits was highly positive, with a significant number of patients expecting virtual visits to be a part of their treatment going forward. These findings indicate that clinics and providers must implement a long-term virtual care solution to remain competitive.

CoachCare providesvirtual health and remote patient monitoring servicesto over 3,500 clinics, and approximately 100,000 providers and patients. Earlier this year, as the healthcare industry found itself forced to evolve into a virtual environment practically overnight due to COVID-19, CoachCare sought to understand how patients were reacting to the new reality. The survey revealed that patients were both accepting and optimistic about the changes to their healthcare routines.

Recommended AI News:Litmus and Oden Partner to Offer Complete IIoT Solution for Smart Manufacturing

Our survey shows that although only a small percentage of patients had used virtual video visits prior to COVID-19, they quickly adjusted. Many patients now prefer virtual care or a combination of virtual and in-person care compared to strictly in-person appointments, said CoachCare Marketing Director, Carol Duke, who ran the survey. This is encouraging news for clinics and providers who are worried their patients will resist virtual care, now and in the future.

Providers in the healthcare space have faced unprecedented changes to their businesses and patient programs as they have been forced to look for ways to continue to care for their patients during COVID-19. Part of the challenge is the need to implement new services and technologies for staff and patients to stay safe, while keeping their clinics open. Today, patient services such as remote patient monitoring and secure video visits are a necessity for providers.

Recommended AI News:S&P Global Market Intelligence Becomes Exclusive Provider of Citigroup Aftermarket Research

The CoachCare survey shows that these virtual technologies are beneficial to both the clinic and patient, allowing clinics an acceptable way to monitor and check on their patients at any time between in-person visits, and providing patients with more flexibility, time, and money when it comes to their healthcare journey.

Secure video visits are just the tip of the iceberg here. Duke continued. COVID has brought to the forefront the need for providers to not only visit with their patients remotely but also to fully monitor their conditions and programs from home, 24/7. This is not something that will go away once COVID passes. Patients will expect personalized remote care moving forward.

All of the survey highlights can be seen below:

Title: Patient Response to Virtual Visits Due to COVID-19

Recommended AI News:ZelaaPayAE Partners with Tron to Empower Users with a Dual Chain Solution

Read more:
90% Of Patients Utilizing Virtual Visits; 63% Say They Want to Continue - AiThority

Tom Hanks and his wife, Rita Wilson, were among the earliest celebrities to catch the novel coronavirus. In an interview at the beginning of July, Hanks described how differently COVID-19 had affected each of them in March.

My wife lost her sense of taste and smell, she had severe nausea, she had a much higher fever than I did. I just had crippling body aches, he said. I was very fatigued all the time and I couldnt concentrate on anything for more than about 12 minutes.

Why does COVID-19 present such different symptoms or none at all in different people?

Preexisting conditions can only be part of the story. Hanks is over 60 and is a Type 2 diabetic, putting him in a high-risk group. Nevertheless, he survived his brush with the virus with no pneumonia and apparently without any long-lasting effects. Knowing what causes variation in different patients could help physicians tailor their treatments to individual patients an approach known as precision medicine.

In recent years, a gene-centric approach to precision medicine has been promoted as the future of medicine. It underlies the massive effort funded by the U.S. National Institutes of Health to collect over a million DNA samples under the All of Us initiative that began in 2015.

But the imagined future did not include COVID-19. In the rush to find a COVID-19 vaccine and effective therapies, precision medicine has been insignificant. Why is this? And what are its potential contributions?

We are a physician geneticist and a philosopher of science who began a discussion about the promise and potential pitfalls of precision medicine before the arrival of COVID-19. If precision medicine is the future of medicine, then its application to pandemics generally, and COVID-19 in particular, may yet prove to be highly significant. But its role so far has been limited. Precision medicine must consider more than just genetics. It requires an integrative omic approach that must collect information from multiple sources beyond just genes and at scales ranging from molecules to society.

Inherited diseases such as sickle cell anemia and Tay-Sachs disease follow a predictable pattern. But such direct genetic causes are perhaps the exception rather than the rule when it comes to health outcomes. Some heritable conditions for instance, psoriasis or the many forms of cancer depend on complex combinations of genes, environmental and social factors whose individual contributions to the disease are difficult to isolate. At best, the presence of certain genes constitutes a risk factor in a population but does not fully determine the outcome for an individual person carrying those genes.

The situation becomes yet more complicated for infectious diseases.

Viruses and bacteria have their own genomes that interact in complex ways with the cells in the people they infect. The genome of SARS-CoV-2 underlying COVID-19 has been extensively sequenced. Its mutations are identified and traced worldwide, helping epidemiologists understand the spread of the virus. However, the interactions between SARS-CoV-2 RNA and human DNA, and the effect on people of the viruss mutations, remain unknown.

Tom Hanks and his wife caught the virus and recovered in a matter of weeks. Presumably each was infected over the course of a few minutes of exposure to another infected person, involving cellular mechanisms that operate on a timescale of milliseconds.

But the drama of their illness, and that of the many victims with far worse outcomes, is taking place in the context of a global pandemic that has already lasted months and may continue for years. People will need to adopt changes in their behavior for weeks or months at a time.

What should a precision medicine approach be in a pandemic? The gene-centric vision of precision medicine encourages people to expect individualized gene-targeted fixes. But, genes, behavior and social groups interact over multiple timescales.

To capture all the data needed for such an approach is beyond possibility in the current crisis. A nuanced approach to the COVID-19 pandemic will depend heavily on imprecise population level public health interventions: mask-wearing, social distancing and working from home. Nevertheless, there is an opportunity to begin gathering the kinds of data that would allow for a more comprehensive precision medicine approach one that is fully aware of the complex interactions between genomes and social behavior.

With unlimited resources, a precision medicine approach would begin by analyzing the genomes of a large group of people already known to be exposed to SARS-CoV-2 yet asymptomatic, along with a similar-sized group with identified risk factors who are dying from the disease or are severely ill.

An early study of this kind by Precisionlife Ltd data mined genetic samples of 976 known COVID-19 cases. Of these, 68 high-risk genes were identified as risk factors for poor COVID-19 outcomes, with 17 of them deemed likely to be good targets for drug developments. But, as with all such statistical approaches, the full spectrum of causes underlying their association with the disease is not something the analysis provides. Other studies of this kind are appearing with increasing frequency, but there is no certainty in such fast-moving areas of science. Disentangling all the relevant factors is a process that will take months to years.

To date, precision medicine has proven better suited to inherited diseases and to diseases such as cancer, involving mutations acquired during a persons lifetime, than to infectious diseases. There are examples where susceptibility to infection can be caused by malfunction of unique genes such as the family of inherited immune disorders known as agammaglobulinemia, but these are few and far between.

Many physicians assume that most diseases involve multiple genes and are thus not amenable to a precision approach. In the absence of the kind of information needed for a multi-omic approach, there is a clear challenge and opportunity for precision medicine here: If it is to be the future of medicine, in order to complement and expand our existing knowledge and approaches, it needs to shift from its gene-centric origins toward a broader view that includes variables like proteins and metabolites. It must consider the relationships between genes and their physical manifestations on scales that range from days to decades, and from molecules to the global society.

Read this article:
How to use precision medicine to personalize COVID-19 treatment according to the patient's genes - The Conversation US

Charlotte, NC Quick question: Are you holding your breath right now? If youre anything like the rest of us you probably answered. Yes.

Holding your breath or breathing at a shallower rate when youre using any kind of screen is a Real Thing. It even has a name: Screen apnea. Others have dubbed it email apnea, or, more recently, Zoom apnea, after the online meeting app.

Screen apnea was first brought to attention by Linda Stone, a writer/researcher, and former Apple and Microsoft executive, who noticed that the vast majority of us hold our breath or breathe shallowly while using screens.

And its getting a lot more attention now that COVID-19 has radically changed the workday for millions of Americans who now spend countless hours transfixed by phone and computer screens. Dreaded meetings that at least offered a chance to connect now mean: more screen time.

So, if Zoom leaves you feeling depleted, know youre not alone. Feeling trapped at your desk under the gaze of multiple moving headshotsisanxiety-provoking.

The performative aspect alone maintaining a pleasant facial expression while others speak, planning a thoughtful response, and being the center of unwavering attention while you talk can cause a sense of stage fright. Big hint: Turning off the camera can help.

The short answer is: Yes, according toDr. Russell GreenfieldofNovant Health Integrative Medicine.

Over time, screen apnea can:

Screen apnea alters your bodys delicate balance of gasses like oxygen, nitric oxide, and carbon dioxide, Greenfield said. This can cause inflammation and interfere with your immune systems ability to fight infection.

Not exactly good news during the coronavirus pandemic, when we all want our immune systems functioning like well-oiled machines.

Its pretty safe to assume weallhave screen apnea to some degree, Greenfield said, as we focus on devices and spend less time on the aspects of our lives that enhance a sense of peace and comfort.

By changing our habits around three key contributing factors of screen apnea posture, stress, and the breath itself Greenfield said we can protect our health and simply feel better day-to-day.

Most of us think of ergonomics in relation to back pain or repetitive-stress injuries. But ergonomics also affects our breathing.

For example, when we work on computers,e lean forward, extend our necks and round our shoulders, while compressing the rib cage. Strategies:

Relying more on email and texts robs us of vital information wed normally get at the workplace: facial expressions, body language, and tone of voice. That makes it easier for misunderstandings, frustration, and anger to flare, which leads to more stress and poor breathing a vicious cycle. Greenfields advice:

Breathing is one of the few critical body functions we can control. Thats good news it means we can retrain ourselves to breathe in a healthier manner, Greenfield said.

We tend to think of our bodies as isolated parts and systems lungs, heart, brain but everything is interrelated, Greenfield said. The truth is: Our breath is intimately connected to multiple aspects of our well-being.

The foundation of almost every meditation practice, including mindfulness-based stress reduction (MBSR), breathing slowly and deeply enables us to be fully present, and to offer our complete attention to whatever were engaged in. To breathe better:

Bottom line: Paying just a little more attention to your body, your screen habits, and your breathing can improve your life, safeguard your health, and keep your resilience strong.

Read the original post:
Why Heavy Zoom and Screen Time is Hazardous to your Health - Mint Hill Times